Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.34 |
| ▸ | TTR | P02766 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 6/20 | 0.32 |
| ▸ | CTSE | P14091 | 6/20 | 0.32 |
| ▸ | BACE1 | P56817 | 4/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Symplostatin 1 SCHEMBL29563593 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4PTPRBFOLH1TTR | |
| Dolastatin-10 SCHEMBL5286 | 0.98 | SSTR2 (0.40) | SSTR2CYP3A4PTPRBFOLH1TTR | |
| Dolastatin-10 SCHEMBL16730776 | 0.98 | SSTR2 (0.40) | SSTR2CYP3A4PTPRBFOLH1TTR | |
| Dolastatin-10 SCHEMBL12016480 | 0.98 | SSTR2 (0.40) | SSTR2CYP3A4PTPRBFOLH1TTR | |
| Dolastatin-10 SCHEMBL6423272 | 0.98 | SSTR2 (0.40) | SSTR2CYP3A4PTPRBFOLH1TTR | |
| Dolastatin-10 SCHEMBL23387006 | 0.98 | SSTR2 (0.40) | SSTR2CYP3A4PTPRBFOLH1TTR | |
| Dolastatin-10 SCHEMBL13378458 | 0.98 | SSTR2 (0.40) | SSTR2CYP3A4PTPRBFOLH1TTR | |
| Dolastatin-10 SCHEMBL22126283 | 0.98 | SSTR2 (0.40) | SSTR2CYP3A4PTPRBFOLH1TTR | |
| Dolastatin-10 SCHEMBL22126284 | 0.98 | SSTR2 (0.40) | SSTR2CYP3A4PTPRBFOLH1TTR | |
| Dolastatin-10 SCHEMBL13135112 | 0.98 | SSTR2 (0.40) | SSTR2CYP3A4PTPRBFOLH1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| US-10220090-B2 | BCMA Antigen binding proteins | AMGEN INC. (US) | 2019-03-05 | — | — | US | claimed |
| US-20190008974-A9 | BCMA ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2019-01-10 | — | — | US | claimed |
| US-20170165373-A1 | BCMA ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2017-06-15 | — | — | US | claimed |
| US-9243058-B2 | BCMA antigen binding proteins | AMGEN, INC. (US) | 2016-01-26 | — | — | US | claimed |
| US-20150344583-A1 | BCMA ANTIGEN BINDING PROTEINS | AMGEN INC. | 2015-12-03 | — | — | US | claimed |
| EP-2928922-A2 | BCMA ANTIGEN BINDING PROTEINS | Amgen Inc. (US) | 2015-10-14 | — | — | EP | claimed |
| US-20140161828-A1 | BCMA ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2014-06-12 | — | — | US | claimed |
| WO-2014089335-A2 | BCMA ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2014-06-12 | — | — | WO | claimed |
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | disclosed |
| US-12583932-B2 | CD38 and ICAM1 antibodies and uses thereof | VIRTUOSO BINCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4684799-A2 | ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF | TrueBinding, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4673181-A1 | USE OF ANTI-CEACAM5 IMMUNOCONJUGATES FOR TREATING NEUROENDOCRINE CANCERS EXPRESSING CEACAM5 | Sanofi (FR) | 2026-01-07 | — | — | EP | disclosed |
| US-12497458-B2 | Anti-GAL3 antibodies and uses thereof | TRUEBINDING, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20050053608-A1 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof | AMGEN FREMONT INC. | 2005-03-10 | — | — | US | disclosed |
| WO-2005012479-A2 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF | ABGENIX, INC (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005010151-A2 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF | ABGENIX, INC (US) | 2005-02-03 | — | — | WO | disclosed |
| US-6638528-B1 | Pressure-sensitive adhesive matrix comprising blend of polyacrylate, polysiloxane, polyisobutylene, polyisoprene, polyamide or polystyrene; and insoluble, non-adhesive ethyl cellulose; polyvinylpyrrolidone crystallization inhibitor | NOVEN PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| WO-2003033523-A2 | CYTOTOXIC COMPOUNDS | INSTITUTO BIOMAR S.A. (ES) | 2003-04-24 | — | — | WO | disclosed |
| US-20020004065-A1 | Compositions and methods to effect the release profile in the transdermal administration of active agents | KANIOS DAVID (US) | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165373-A1 | BCMA ANTIGEN BINDING PROTEINS | CD79B, BCR, BCDIN3D | SSTR2 4170/4885CYP3A4 4671/4885PTPRB 68/4885 |
| US-20150344583-A1 | BCMA ANTIGEN BINDING PROTEINS | CD79B, BCR, BCAP31 | SSTR2 4231/4885CYP3A4 4741/4885PTPRB 79/4885 |
| US-20190008974-A9 | BCMA ANTIGEN BINDING PROTEINS | CD79B, BCR, BCDIN3D | SSTR2 4170/4885CYP3A4 4671/4885PTPRB 68/4885 |
| US-20140161828-A1 | BCMA ANTIGEN BINDING PROTEINS | CD79B, BCR, BCDIN3D | SSTR2 4170/4885CYP3A4 4671/4885PTPRB 68/4885 |
| US-12583932-B2 | CD38 and ICAM1 antibodies and uses thereof | FCGR2A, FCGR3B, FCGR1A | SSTR2 1696/4885CYP3A4 4262/4885PTPRB 521/4885 |
| US-10220090-B2 | BCMA Antigen binding proteins | CD79B, BCR, BCDIN3D | SSTR2 4170/4885CYP3A4 4671/4885PTPRB 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.